Hematology Branch, NHLBI, NIH Bldg. 10, CRC 3-5140, 10 Center Drive, Bethesda, 20892-1202 USA.
Haematologica. 2010 Feb;95(2):329-32. doi: 10.3324/haematol.2009.012484. Epub 2009 Aug 13.
A pilot study previously demonstrated that thrice-weekly, fractionated-dose intravenous rituximab (RTX) limits CD20 loss from chronic lymphocytic leukemia (CLL) B cells, thereby enhancing immunotherapeutic targeting. Here, we investigated the feasibility of giving 20 mg rituximab subcutaneously thrice weekly for up to 12 weeks in 4 previously treated CLL patients. Subcutaneous rituximab was well-tolerated with minimal injection site reactions; a variable degree of efficacy was observed, likely influenced by the size of the patients' B cell/CD20 burden. Subcutaneous RTX largely preserved CD20 expression on leukemic cells but the most effective therapeutic dosing regimen needs to be established (ClinicalTrials.gov Identifier: NCT00366418).
先前的一项初步研究表明，每周三次、分剂量静脉注射利妥昔单抗（RTX）可限制慢性淋巴细胞白血病（CLL）B 细胞中 CD20 的丢失，从而增强免疫治疗的靶向性。在此，我们研究了每周三次皮下给予 20mg 利妥昔单抗长达 12 周的可行性，共纳入 4 例先前接受过治疗的 CLL 患者。皮下利妥昔单抗耐受性良好，仅有轻微的注射部位反应；观察到疗效存在一定程度的差异，可能与患者 B 细胞/CD20 负荷的大小有关。皮下 RTX 很大程度上保留了白血病细胞上的 CD20 表达，但需要确定最有效的治疗剂量方案（ClinicalTrials.gov 标识符：NCT00366418）。
